Stryker Co. (NYSE:SYK) has been assigned a consensus recommendation of “Buy” from the twenty-two research firms that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $201.41.
Several equities research analysts have weighed in on SYK shares. Deutsche Bank raised their target price on shares of Texas Instruments from $100.00 to $110.00 and gave the company a “hold” rating in a research note on Wednesday, April 24th. Credit Suisse Group set a $82.00 target price on shares of InterXion and gave the company a “buy” rating in a research note on Thursday. Wells Fargo & Co restated a “hold” rating on shares of Perrigo in a research note on Tuesday, July 2nd. ValuEngine upgraded shares of Yirendai from a “strong sell” rating to a “sell” rating in a research note on Friday, May 3rd. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $68.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, April 24th.
In related news, insider Timothy J. Scannell sold 4,666 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $192.40, for a total transaction of $897,738.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Louise Francesconi sold 2,679 shares of the firm’s stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $187.25, for a total transaction of $501,642.75. Following the transaction, the director now directly owns 15,598 shares of the company’s stock, valued at approximately $2,920,725.50. The disclosure for this sale can be found here. Insiders have sold 21,377 shares of company stock valued at $4,081,972 over the last quarter. Insiders own 7.20% of the company’s stock.
Several institutional investors have recently modified their holdings of SYK. Norges Bank purchased a new position in shares of Stryker during the fourth quarter worth $474,132,000. FMR LLC raised its holdings in shares of Stryker by 13.4% during the first quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock worth $1,328,951,000 after purchasing an additional 793,560 shares during the last quarter. GQG Partners LLC purchased a new position in shares of Stryker during the fourth quarter worth $116,175,000. Ellis Investment Partners LLC raised its holdings in shares of Stryker by 19,658.9% during the first quarter. Ellis Investment Partners LLC now owns 367,318 shares of the medical technology company’s stock worth $367,000 after purchasing an additional 365,459 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Stryker by 66.2% during the fourth quarter. Deutsche Bank AG now owns 863,390 shares of the medical technology company’s stock worth $135,330,000 after purchasing an additional 343,913 shares during the last quarter. 73.58% of the stock is owned by hedge funds and other institutional investors.
SYK traded down $4.44 during trading on Tuesday, hitting $206.40. The stock had a trading volume of 1,704,626 shares, compared to its average volume of 901,367. The stock has a market cap of $77.01 billion, a P/E ratio of 28.24, a PEG ratio of 2.50 and a beta of 0.87. Stryker has a twelve month low of $144.75 and a twelve month high of $210.85. The company has a quick ratio of 1.30, a current ratio of 2.12 and a debt-to-equity ratio of 0.68. The business’s 50 day simple moving average is $197.39.
Stryker (NYSE:SYK) last announced its earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.84 by $0.04. The company had revenue of $3.52 billion during the quarter, compared to the consensus estimate of $3.51 billion. Stryker had a net margin of 25.38% and a return on equity of 26.72%. Stryker’s revenue was up 8.5% compared to the same quarter last year. During the same period last year, the firm earned $1.68 earnings per share. On average, sell-side analysts anticipate that Stryker will post 8.15 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $2.08 annualized dividend and a dividend yield of 1.01%. Stryker’s payout ratio is currently 28.45%.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: What is a bull market?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.